Universität zu Köln

Schaub, F., Neuhann, I., Enders, P., Bachmann, B. O., Koller, B., Neuhann, T. and Cursiefen, C. (2018). Boston keratoprosthesis: 73 eyes from Germany. An overview of experiences from two centers. Ophthalmologe, 115 (9). S. 744 - 754. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0423

Full text not available from this repository.

Abstract

The Boston Keratoprosthesis (B-KPro) is atherapeutic option for corneal replacement for visual rehabilitation in eyes with poor a prognosis for penetrating keratoplasty (high-risk eyes). Since 2009, this approach has been used in the MVZ Prof. Neuhann, Munich, and since 2013 also at the Department of Ophthalmology, University of Cologne. An overview of results from the first 73eyes in these departments is presented.MethodsAll recipient eyes of both centers which received aB-KPro typeI (BI-KPro) between November 2009 and March 2017 were included. Indications, preoperative findings, intraoperative procedures, and clinical results, as well as postoperative complication and retention rates were documented and analyzed.ResultsAtotal of 73eyes from 68patients (mean age 55 +/- 21.1years, range 7months-93years; 26women, 42men) were treated with aBI-KPro. In 53eyes (72.6%) the BI-KPro was implanted due to corneal graft failure, whereas BI-KPro was used as the primary corneal replacement in 20eyes (27.4%). In 46eyes (63.0%) along-term increase in visual acuity was achieved and in 21.9% visual acuity was stabilized, while adecrease in preoperative visual acuity occurred in 15.1% of cases. During an average follow-up of 24.7 +/- 23.0months (range 1-78months), 1.7 +/- 2.4 re-interventions (range 0-9) were required. Only 4keratoprostheses (5.5%) could not be retained. In 3eyes (4.2%), achange of the BI-KPro device was necessary.ConclusionThere is awide range of indications for BI-KPro in eyes with apoor prognosis for conventional keratoplasty. The surgical technique is safe but with anotable postoperative complication rate, which does not seem to decrease in the medium or long term. The retention rate is excellent for eyes without stem cell deficiency. Nevertheless, the BI-KPro is the only therapeutic option for high-risk eyes and leads to again in visual acuity in most cases.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schaub, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Neuhann, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Enders, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bachmann, B. O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Koller, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Neuhann, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cursiefen, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-174969
DOI:	10.1007/s00347-017-0581-0
Journal or Publication Title:	Ophthalmologe
Volume:	115
Number:	9
Page Range:	S. 744 - 754
Date:	2018
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0423
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language LONG-TERM OUTCOMES; TYPE-1 KERATOPROSTHESIS; KERATOLIMBAL ALLOGRAFT; INTRACTABLE GLAUCOMA; CROSS-LINKING; KERATOPLASTY; MULTICENTER; COMPLICATIONS; RETINECTOMY; INFLIXIMAB Multiple languages Ophthalmology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/17496